Can a Chemo-Free pill combo outsmart leukemia at first diagnosis?

NCT ID NCT06319456

Recruiting now Disease control Sponsor: Ascentage Pharma Group Inc. Source: ClinicalTrials.gov ↗

First seen Jul 28, 2026 · Last updated Jul 29, 2026 · Updated 1 time

Summary

This phase 3 trial is testing whether a combination of two targeted oral drugs—lisaftoclax and acalabrutinib—can work better than standard chemoimmunotherapy for people newly diagnosed with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). About 344 participants will be randomly assigned to receive either the two-drug combo or a standard chemo regimen. The main goal is to see if the combo helps people live longer without their cancer progressing.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: a combination of two oral drugs: lisaftoclax (a BCL-2 inhibitor) and acalabrutinib (a BTK inhibitor)
What this could lead to: If successful, this drug combination could offer a more targeted, chemotherapy-free option for people newly diagnosed with CLL/SLL, potentially improving how long they live without their disease getting worse.
What could go wrong: This is an early confirmatory trial, so the combination may not prove more effective than current treatments. Side effects from the two drugs together are still being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell chronic lymphocytic leukemia chronic lymphocytic leukemia/small lymphocytic lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CLL / SLL

Contacts and locations

Locations

Guangdong Provincial People's Hospital
RECRUITING

Guangzhou, Guangdong, 510080, China
Hematology Hospital of the Chinese Academy of Medical Sciences
RECRUITING

Tianjin, Tianjin Municipality, 300020, China
Henan Provincial Cancer Hospital
RECRUITING

Zhengzhou, Henan, 450003, China
Hunan Cancer Hospital
NOT_YET_RECRUITING

Changsha, Hunan, 410031, China
Nanfang Hospital of Southern Medical University
RECRUITING

Guangzhou, Guangdong, 510515, China
The First Affiliated Hospital of Bengbu Medical College
NOT_YET_RECRUITING

Bengbu, Anhui, 233004, China
The Second Xiangya Hospital of Center South University
NOT_YET_RECRUITING

Changsha, Hunan, 545001, China
The affiliated Hospital of Guangdong Medical University
NOT_YET_RECRUITING

Zhanjiang, Guangdong, 524013, China
Tongji Hospital of Tongji University
NOT_YET_RECRUITING

Shanghai, Shanghai Municipality, 200065, China
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
NOT_YET_RECRUITING

Wuhan, Hubei, 430023, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.